BioSpace News Archive

Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, today announced that it has raised $98 million in a Series C financing. The financing was led b

Data supports a differentiated gp96-based COVID-19 vaccine that induces systemic and tissue-specific (lung) memory CD8+ T cells Gp96-based vaccine generates tissue-resident memory CD8+ T cells that may be instrumental in eradicating SARS-CoV-2 infected cells Tissue specific memory CD8+ T cells potentially important for compromised patient populations

Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that Terrence W. Norchi, MD, Chief Executive Officer, will present at the LD 500 Virtual Conference on Tuesday, September 1st, 2020

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Shockwave management is scheduled to speak at the following upcoming virtual investor conferences

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Mapp Biopharmaceutical, Inc.,

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce new data is scheduled to be presented in four poster presentations at the ESMO Virtual Congress 2020 which is being held from 19 to 21 September 2020, Central European Summer Time (CEST).

ONS-5010, an investigational ophthalmic formulation of bevacizumab-vikg for the treatment of wet AMD, demonstrated safety and efficacy profile consistent with previously published ophthalmic bevacizumab research NORSE 1 results support trial design and inclusion criteria for fully enrolled, ongoing pivotal NORSE 2 registration trial MONMOUTH JUNCTION, N.J., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company work

OS Therapies, and late-stage clinical research biotechnology company focused on Osteosarcoma and other solid tumors today announced the co-exclusive licensing of BlinkBio’s novel Si-Linker and Cassette Payload technologies, and exclusive licensing of the BlinkBio technology to target Folate Receptor Alpha (FRα) for tumors and other targeted diseases. Antibody Drug Conjugates (ADC) technology has been the focus of intense interest t

Columbus Citizens Foundation (CCF) is proud to announce a new scholarship to support Italian Americans with great academic prowess seeking financial aid at the graduate level in medical and public health fields of study.

Ivy Brain Tumor Center at Barrow Neurological Institute announced today a new collaboration with Vivace Therapeutics.